Esperion Therapeutics’ shares fall after disclosing uncertain future for its cholesterol-lowering drug

Tim Casey | | Cardiovascular Business | Economics

Shares of Esperion Therapeutics’ common stock have plunged this week after the company said the future of its investigational cholesterol-lowering drug remains murky. The FDA told the company that it might require a cardiovascular outcomes study before approving the medication, according to Forbes.

Read more of the article below:

Can Esperion Therapeutics Ever Regain Wall Street's Trust?

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access
Abbott opens CGM sensor manufacturing facility in Ireland as part of $465M investment
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Cardiologist demand is on the rise—can hospitals keep up?
Cardiologist receives 35 months in prison for health insurance fraud

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."